Protalix BioTherapeutics is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases. The company utilizes its proprietary ProCellEx plant cell-based protein expression system to produce recombinant proteins. Its commercial portfolio includes Elelyso (taliglucerase alfa) for Gaucher disease and Elfabrio (pegunigalsidase alfa) for Fabry disease. Protalix is developing pipeline candidates such as PRX-115 for uncontrolled gout and PRX-119 for NETs-related diseases. The company partners with Pfizer for the commercialization of Elelyso in most markets and with Chiesi for the global development and commercialization of Elfabrio. In Brazil, Elelyso is marketed as BioManguinhos alfataliglicerase in partnership with Fiocruz. Protalix serves patients in the United States, the European Union, Brazil, and other markets.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage protalix.com
Sector Healthcare IR page ir.protalix.com
Tags
rare diseases, enzyme replacement therapy, plant cell expression, recombinant proteins, pegylation, gaucher disease, fabry disease, gout, protein therapeutics, ProCellEx, Elelyso, taliglucerase alfa, Elfabrio, pegunigalsidase alfa, PRX-115, PRX-119, BioManguinhos alfataliglicerase, Pfizer, Chiesi, Fiocruz
Press page —

Metrics

Valuation  
Market cap $ 232.72M
Market cap (USD) $ 232.72M
P/E 10.62
PEG —
P/BV 2.89
P/S 2.75
P/OCF 13.25
P/FCF 15.45
Dividend yield —
Turnover / mcap —
Returns  
ROE -14.4%
ROI -16.3%
ROIC -10.2%
Profit margin -12.5%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 35
Quality score -58.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001
Revenue 52.744M 53.399M 65.494M 47.638M 38.35M 62.898M 54.693M 18.854M 19.242M 9.199M 4.364M 13.651M 10.479M 34.87M 8.386M 6.642M — — — — — — — — —
Net profit -6.604M 2.932M 8.312M -14.927M -27.582M -6.523M -18.276M -26.457M -85.276M -29.365M 58.037M -29.943M -27.79M -11.618M -36.529M -28.998M -31.44M — — — -74.931K -160.07K -140.714K -149.762K -329.173K
Free cash flow -13.631M 7.392M -2.467M -25.628M -11.744M -26.761M -19.985M -8.428M -10.965M -32.947M -24.748M -30.066M -32.543M -1.433M -29.275M -46.319M 38.257M — — — — — — — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001
Share price 1.8 1.88 1.78 1.37 0.83 3.63 3.28 0.31 0.66 0.45 1.02 1.84 3.89 5.52 4.91 9.67 6.63 1.64 3.4 — — — — — —
Price performance 12m -0.04 0.06 0.3 0.65 -0.77 0.11 9.55 -0.53 0.49 -0.56 -0.45 -0.53 -0.3 0.12 -0.49 0.46 3.05 -0.52 — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 693,000 1.72M 4.73M 4.7M 2M 3.44M 4.59M 5.27M 2.91M 8.84M
↳ YoY growth +148.3% +174.8% -0.6% -57.4% +72.1% +33.2% +15.0% -44.8% +203.9%
↳ 5y CAGR -12.8% +4.1% +17.7% +20.1% +37.8% +21.7% +2.2% -9.1% +34.6%
Lease liabilities (USD) — — 5.7M 5.67M 5.89M 5.58M 5.29M 6.03M 5.53M 8.32M
Cash and deposits (USD) 63.3M 51.2M 37.8M 17.8M 18.3M 39M 17.1M 23.6M 19.8M 14.7M
Right-of-use assets (USD) — — 0.00 5.68M 5.6M 4.96M 5.09M 5.91M 5.43M 7.7M
Cash flow detail
Operating cash flow (USD) -32.1M -9.99M -7.74M -19.4M -26.1M -10.3M -25M -1.32M 8.67M -12M
Purchases of property, plant and equipment (USD) -849,000 -971,000 -686,000 -627,000 -655,000 -1.46M -628,000 -1.15M -1.28M -1.64M
Change in receivables (cash effect) (USD) -1.13M 25,000 -3.1M 188,000 2.09M -1.03M -1.19M -428,000 2.32M -5.89M
Change in inventories (cash effect) (USD) 522,000 -2.59M -736,000 414,000 -4.93M -4.87M 1.15M -2.24M -2.2M -4.49M
Change in payables (cash effect) (USD) 2.14M 4.9M -761,000 2.74M 2.27M 2.39M -4.8M 5.3M 696,000 292,000
Interest paid (cash effect) (USD) -3.66M -4.85M -4.59M -4.34M -4.34M -3.41M -2.2M -2.74M -1.53M 0.00
Income taxes paid (cash effect) (USD) — — — — — — — — -385,000 -1.18M
Share-based compensation (USD) 988,000 337,000 514,000 835,000 3.13M 2.38M 2.09M 3.45M 3.25M 2.3M
Operating cash flow before change in receivables (USD) -31M -10M -4.64M -19.5M -28.2M -9.25M -23.8M -890,000 6.36M -6.1M
Free cash flow (OCF - PPE - intangibles) (USD) -32.9M -11M -8.43M -20M -26.8M -11.7M -25.6M -2.47M 7.39M -13.6M
Income detail
Research and development expense (USD) 30.4M 32.2M 35.5M 44.7M 38.2M 29.7M 29.3M 17.1M 13M 19.6M
↳ 5y CAGR -4.3% -2.6% +1.3% +8.5% +8.9% -0.4% -1.8% -13.6% -21.9% -12.5%
Reported Mar 16, 2017 Mar 6, 2018 May 6, 2019 Mar 12, 2020 Mar 30, 2021 Mar 31, 2022 Feb 27, 2023 Mar 14, 2024 Mar 17, 2025 Mar 18, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Company to host conference call and webcast today at 8:00 a.m. ET

● Total revenues increased by $32.0 million year to date to $75.6 million, from $43.6 million for the same period in 2025

● Net income was $4.0 million for the third quarter, up from $2.4 million in the third quarter of 2025, and net income was $26.1 million for the nine months ended September 30, 2026

● Management expects to meet or exceed 2026 guidance for total revenues of approximately $78.0 million to $83.0 million

● The PRX-115 Phase 2 RELEASE study remains on track, aiming to improve adherence and durability of response in uncontrolled gout, a substantial unmet need; top-line results anticipated in the second half of 2027

● Cash, cash equivalents, and short-term bank deposits were $48.5 million as of September 30, 2026

CARMIEL, Israel, November 10, 2026 -- Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today reported financial results for the third quarter ended September 30, 2026, and provided a business and clinical update.

November 3, 2026

PDF Version

Company to host conference call and webcast at 8:00 a.m. ET

CARMIEL, Israel, Nov. 3, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that it will release its financial results for the quarter ended September 30, 2026 and provide a business update on November 10, 2026.

Protalix Biotherapeutics Logo

Management will host a conference call to discuss the financial results and provide an update on recent corporate and regulatory developments.

**Conference Call Details:**Date: Tuesday, November 10, 2026 Time: 8:00 a.m. Eastern Time (ET) Toll Free: 1-877-423-9813 International: 1-201-689-8573 Israeli Toll Free: 1-809-406-247 Conference ID: 13763420 Call me™:https://tinyurl.com/3awxvdvm The Call me™ feature allows you to avoid the wait for an operator; you enter your phone number on the platform and the system calls you right away.

**Webcast Details:**The conference will be webcast live from the Protalix website and will be available via the following links:

Company Link: https://ir.protalix.com/news-events/eventsWebcast Link: https://tinyurl.com/ye6k6b3nConference ID: 13763420

Participants are requested to access the call at least 15 minutes ahead of the conference to register, download and install any necessary audio software. A replay of the call will be available for two weeks on the Events Calendar of the Investors section of the Company's website, at the above link.

About Protalix BioTherapeutics, Inc.

Protalix is a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases. Protalix has researched, developed, and currently manufactures two enzyme replacement therapies that are currently available in multiple markets. These therapies are recombinant therapeutic proteins expressed through Protalix's proprietary plant cell-based expression system, ProCellEx®. ProCellEx is a unique plant cell-based system that enables Protalix to produce recombinant proteins in an industrial-scale manner with no exposure to mammalian cells. Protalix is the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights to taliglucerase alfa, Elelyso®, for the treatment of Gaucher disease, excluding in Brazil where Protalix retains full rights.

Protalix has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio® which was approved by both the FDA and the European Medicines Agency (EMA) in May 2023. Protalix's development pipeline includes, among others, two proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets: PRX–115, a plant cell-expressed recombinant PEGylated uricase for the treatment of uncontrolled gout; and PRX–119, a plant cell-expressed long-acting DNase I for the treatment of NETs-related diseases. To learn more, please visit www.protalix.com.

Investor ContactMike Moyer, Managing Director LifeSci Advisors +1-617-308-4306 [email protected]

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-announce-third-quarter-2026-financial-results-and-business-update-on-november-10-2026-302927769.html

SOURCE Protalix BioTherapeutics, Inc.

Back to top

October 26, 2026

PDF Version

CARMIEL, Israel, Oct. 26, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that Dror Bashan, President and Chief Executive Officer, is scheduled to present at the Stifel 2026 Healthcare Conference. The Conference is being held on November 10-12, 2026 at the Lotte New York Palace Hotel, New York City, NY.

Protalix Biotherapeutics Logo

Mr. Bashan will provide a live corporate overview on Tuesday, November 10, at 2:00 p.m. Eastern Time in the Hubbard Room, Fifth Floor, and the Company's management will participate in one-on-one meetings with registered investor attendees. Investors interested in arranging a meeting should contact their Stifel representative.

A live webcast of Mr. Bashan's presentation will be available at https://event.summitcast.com/view/4aFtJriVa3BvDmNqmfSxma/5NTTgZrQJMJZ8iJS8xzFwq, and on the Events Calendar of the Investors section of the Company's website, www.protalix.com. An archived replay will be available following the event.

About Protalix BioTherapeutics, Inc.

Protalix is a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases. Protalix has researched, developed, and currently manufactures two enzyme replacement therapies that are currently available in multiple markets. These therapies are recombinant therapeutic proteins expressed through Protalix's proprietary plant cell-based expression system, ProCellEx®. ProCellEx is a unique plant cell-based system that enables Protalix to produce recombinant proteins in an industrial-scale manner with no exposure to mammalian cells. Protalix is the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights to taliglucerase alfa, Elelyso®, for the treatment of Gaucher disease, excluding in Brazil where Protalix retains full rights.

Protalix has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio® which was approved by both the FDA and the European Medicines Agency (EMA) in May 2023. Protalix's development pipeline includes, among others, two proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets: PRX–115, a plant cell-expressed recombinant PEGylated uricase for the treatment of uncontrolled gout; and PRX–119, a plant cell-expressed long-acting DNase I for the treatment of NETs-related diseases. To learn more, please visit www.protalix.com.

Investor Contact

Mike Moyer, Managing Director LifeSci Advisors +1-617-308-4306 [email protected]

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-present-at-the-stifel-2026-healthcare-conference-302919245.html

SOURCE Protalix BioTherapeutics, Inc.

Back to top

Prompts

Protalix BioTherapeutics, Inc. (DE) (ticker PLX), listed in United States.

Company History

Date Change Detail
Mar 2, 2007 Renamed ORTHODONTIX INC → PROTALIX BIOTHERAPEUTICS, INC.

ETFs Holding Protalix BioTherapeutics, Inc. (DE)

ETF Weight in ETF Shares Market value As of
AVDS 0.01% 11,694 $ 35.433K Nov 16, 2026
DFAS 0.00% 245,411 $ 726.417K Nov 12, 2026
DFAT 0.00% 130,383 $ 385.934K Nov 12, 2026
DXUV 0.00% 18,521 $ 54.822K Nov 12, 2026
EBI 0.00% 701 $ 1,801.57 Aug 31, 2026
DFAU 0.00% 7,617 $ 22.546K Nov 12, 2026
DFSV 0.00% 15,500 $ 45.88K Nov 12, 2026
DCOR 0.00% 10,500 $ 31.08K Nov 12, 2026
DFAC 0.00% 10,251 $ 30.343K Nov 12, 2026
AVDV 0.00% 15,523 $ 47.035K Nov 16, 2026